Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:
“Fantastic news from monarchE – 2 years of adjuvant abemaciclib for patients with high risk HR+ Breast Cancer improves overall survival.
Happy for SCRI Oncology Partners, Sarah Cannon Research Institute to have participated in this trial and happy for our patients to have had access early. Translating more patients to cure is a very powerful way endpoint. ”
More posts featuring Erika Hamilton on OncoDaily.